Author:
Morse Rachel M.,Brown Joanna,Noble Helen E.,Ríos López E. Jennifer,Kohler-Smith Anna,Soto Sandra,del Cuadro Daniel Lenin,Gonzales Díaz Karina,Figueredo Escudero Magaly,Vásquez del Aguila Giannina,Carrillo Jara Lita E.,Silva Delgado Hermann F.,Palacios Victor A.,Santos-Ortiz Carlos,Gravitt Patti E.,Paz-Soldan Valerie A.,Del Carpio-Morgan Meda,Garcia Satalay Esther Y.,Gilman Sarah D.,Jerónimo José,Jorges Alcedo,Jurczuk Magdalena,Kosek Margaret,Ladrón de Guevarra Gabriela,Lopez Liñán Renso,Matos Orbegozo Andrea,Marín Jaime,Meza Graciela,Ríos Reátegui Reyles,Román Karina,Rositch Anne F.,Tangoa Nolberto,Vásquez Vásquez Javier,Vásquez del Aguila Giannina,Zevallos Karen,
Abstract
Abstract
Background
The objective of this study was to explore women’s experiences of a screen-and-treat approach with ablative therapy (referred to by the Spanish acronym TVT-TA) as a method of treatment following a positive HPV test in Iquitos, Peru.
Methods
A total of 111 in-depth interviews were conducted with 47 HPV positive women who attended the TVT-TA procedure at a primary-level healthcare facility. Interviews were conducted immediately before, immediately after, and six-weeks after TVT-TA.
Results
Most interviewed women reported experiencing moderate pain during ablative therapy and minimal pain immediately after and six weeks after ablative therapy. Women also stated that the pain was less intense than they had expected. The most common physical after-effects of treatment were bleeding and vaginal odor. Women experienced oscillating emotions with fear upon receiving a positive HPV result, calming after hearing about ablative therapy treatment, worry about pain from the treatment itself, relaxation with counseling about the procedure, and relief following treatment.
Conclusions
Nearly all participants emphasized that they were pleased with the TVT-TA process even if they had experienced pain during TVT-TA, recommended that TVT-TA be expanded and available to more women, and stated that TVT-TA was faster and easier than expected. This study found that TVT-TA is a feasible and acceptable means of treating HPV according to the women receiving the treatment.
Funder
Fogarty International Center’s Northern Pacific Global Health Consortium
US National Cancer Institute
Publisher
Springer Science and Business Media LLC
Subject
Obstetrics and Gynecology,Reproductive Medicine,General Medicine
Reference27 articles.
1. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021. https://doi.org/10.1002/ijc.33588.
2. World Health Organization. WHO guidelines for the use of thermal ablation for cervical pre-cancer lesions. 2019. https://www.who.int/reproductivehealth/publications/thermal-ablation-for-cervical-pre-cancer-lesions/en/. Accessed 28 Feb 2022.
3. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019. https://doi.org/10.1002/ijc.31937
4. Venegas Rodríguez GG. Guía de Práctica Clínica para la Prevención y Manejo del Cáncer de Cuello Uterino [Clinical Practice Guideline for Prevention and Management of Cervical Cancer]. Robles Guerrero L, Yancourt Ruíz S, Chevarría Villafuerte J, editors. Ministerio de Salud; 2017. http://bvs.minsa.gob.pe/local/MINSA/4146.pdf. Accessed 28 Feb 2022.
5. Borja Rojas WE, Roles Guerrero RG, Atarama Cordero MA, editors. Plan nacional para la prevención y control de cáncer de cuello uterino 2017–2021 [National plan for the prevention and control of cervical cancer]. Ministerio de Salud; 2017. http://bvs.minsa.gob.pe/local/MINSA/4232.pdf. Accessed 28 Feb 2022.